Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN8025 in Advanced Solid Tumors
NCT07639047Phase 1Recruiting
- Sponsor
- Adlai Nortye
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AN8025 in solid tumor (advanced stage), sponsored by Adlai Nortye. Primary endpoints: Safety of AN8025 at 24 months and Minimum Tolerated Dose/Recommended Dose for Expansion at 28 days. Started Nov 2025; status: recruiting.
02
Drugs
AN8025
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07639047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639047.